Interviews - Ron Squarer, Chief Executive of Array BioPharma (NASDAQ: ARRY), sits down with PropThink.com to discuss the company’s pipeline, positioning, and commercialization strategies. Squarer says robust … Continue Reading
Read NowInterviews - In an exclusive video interview with PropThink.com, Cynosure (NASDAQ: CYNO) President and CEO Michael Davin discusses Cynosure’s expanding position in the global market as a … Continue Reading
Read NowInterviews - Mesoblast (ASX: MSB) (OTC:MEOBF) CEO Silviu Itesu speaks on his company’s adult stem cell technology, particularly mesenchymal precursor cells, and the low-cost manufacturing capabilities that … Continue Reading
Read NowInterviews - Atrium Innovations’ (TSX:ATB) (PINK:ATBIF) President and CEO Pierre Fitzgibbon discusses the company’s vertical integration, explaining that it allows for more control in tighter regulatory situations. … Continue Reading
Read NowInterviews - In an exclusive video interview with PropThink.com, Michael Bailey, Chief Commercial Officer of AVEO Pharmaceuticals (NASDAQ:AVEO), explains the benefits of AVEO’s Phase III drug candidate … Continue Reading
Read NowInterviews - In an exclusive video interview with PropThink.com, Ablynx (EBR:ABLX)(OTC:ABLYF) CEO Dr. Edwin Moses discusses the company’s platform Nanobody technology – 1/10th the size of traditional … Continue Reading
Read NowInterviews - In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF) CEO Patrik De Haes discusses the company’s pending FDA and EMA approvals of ocriplasmin, a treatment for … Continue Reading
Read Now